Robert Harrington to Prospective Studies
This is a "connection" page, showing publications Robert Harrington has written about Prospective Studies.
Connection Strength
0.410
-
Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. Eur Heart J. 2019 09 01; 40(33):2801-2809.
Score: 0.024
-
Comparison of Rates of Bleeding and Vascular Complications Before, During, and After Trial Enrollment in the SAFE-PCI Trial for Women. Circ Cardiovasc Interv. 2019 05; 12(5):e007086.
Score: 0.024
-
Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials. JAMA Cardiol. 2017 02 01; 2(2):127-135.
Score: 0.020
-
Cangrelor With and Without Glycoprotein?IIb/IIIa Inhibitors in?Patients?Undergoing Percutaneous?Coronary Intervention. J Am Coll Cardiol. 2017 Jan 17; 69(2):176-185.
Score: 0.020
-
Feasibility of Obtaining Measures of Lifestyle From a Smartphone App: The MyHeart Counts Cardiovascular Health Study. JAMA Cardiol. 2017 01 01; 2(1):67-76.
Score: 0.020
-
Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. J Am Heart Assoc. 2016 06 21; 5(6).
Score: 0.019
-
Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial. Circ Cardiovasc Interv. 2016 06; 9(6).
Score: 0.019
-
A registry-based randomized trial comparing radial and femoral approaches in women undergoing percutaneous coronary intervention: the SAFE-PCI for Women (Study of Access Site for Enhancement of PCI for Women) trial. JACC Cardiovasc Interv. 2014 Aug; 7(8):857-67.
Score: 0.017
-
Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial). Am J Cardiol. 2014 Sep 01; 114(5):665-73.
Score: 0.017
-
Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2014 Apr 22; 63(15):1493-9.
Score: 0.017
-
Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome). J Am Coll Cardiol. 2014 Mar 25; 63(11):1048-57.
Score: 0.016
-
Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention). J Am Coll Cardiol. 2014 Feb 25; 63(7):619-629.
Score: 0.016
-
Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2014 Jan 21; 129(3):293-303.
Score: 0.016
-
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation. 2013 Sep 03; 128(10):1055-65.
Score: 0.016
-
Outcomes among non-ST-segment elevation acute coronary syndromes patients with no angiographically obstructive coronary artery disease: observations from 37,101 patients. Eur Heart J Acute Cardiovasc Care. 2014 Mar; 3(1):37-45.
Score: 0.016
-
A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: design of the RENEW study. Am Heart J. 2013 Jun; 165(6):854-861.e2.
Score: 0.016
-
Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA?CER) trial. Eur Heart J. 2013 Jun; 34(23):1723-31.
Score: 0.016
-
Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy). Am J Cardiol. 2011 Dec 01; 108(11):1542-6.
Score: 0.014
-
Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res. 2011 Aug 05; 109(4):428-36.
Score: 0.014
-
Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ. 2011 Jun 17; 342:d3527.
Score: 0.014
-
Smoking status and antithrombin therapy in patients with non-ST-segment elevation acute coronary syndrome. Am Heart J. 2008 Jul; 156(1):177-84.
Score: 0.011
-
Impact of saphenous vein graft radiographic markers on clinical events and angiographic parameters. Ann Thorac Surg. 2008 Feb; 85(2):520-4.
Score: 0.011
-
Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA. 2007 Apr 18; 297(15):1657-66.
Score: 0.010
-
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med. 2006 Sep 07; 355(10):1006-17.
Score: 0.010
-
The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale. Am Heart J. 2005 Jun; 149(6):994-1002.
Score: 0.009
-
The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. J Invasive Cardiol. 2003 Nov; 15(11):611-6.
Score: 0.008